Low-Dose Rivaroxaban Plus Aspirin in Patients With Pe
Undergoing Lower Extremity Revascularization With a
Coronary Artery Disease: Insights From VOYAGER PAD

Circulation

149, 1536-1539

DOI: 10.1161/circulationaha.124.068080

Citation Report

#	Article	IF	Citations
1	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
2	Safety and Efficacy of Combined Coronary and Peripheral Percutaneous Revascularization: A Proof-of-Concept Study. Journal of Clinical Medicine, 2024, 13, 4516.	3.8	1
3	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
4	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
5	Prevalence of Extracranial Carotid Artery Disease in Symptomatic Peripheral Artery Disease and Implications for Long-Term Outcome. Annals of Medicine, 2025, 57, 2478313.	5.0	1
6	Long-Term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence. Clinical Therapeutics, 2025, 47, 511-518.	3.4	4
7	The Impact of Coronary Artery Disease in Patients With Peripheral Artery Disease Undergoing Lower-Extremity Revascularization for Chronic Limb-Threatening Ischemia. Circulation, 2025, 152, 346-348.	24.6	1
8	GLP-1 Receptor Agonists Associated With Improved Survival After Infrainguinal Bypass in Diabetic Patients. Annals of Vascular Surgery, 2025, 121, 480-491.	1.8	4
9	Peripheral Artery Disease. Nature Reviews Disease Primers, 2025, 11, 68.	81.2	41
10	Antiplatelet Therapy for Peripheral Arterial Disease. , 2025, .		0
11	Prevalence, Determinants, and Prognostic Impact of Polyvascular Disease in Patients Hospitalised for Atherosclerosis in Slovenia: A Nationwide, Retrospective Cohort Study. EClinicalMedicine, 2025, 89, 103542.	13.5	0
12	Fatal Coronary Atherosclerosis in the Young: Rethinking Systemic Disease Paradigms?. European Journal of Preventive Cardiology, 2026, 33, 1641-1642.	6.1	0
13	Eligibility for Dual Pathway Inhibition in Patients With Peripheral Artery Disease Undergoing Revascularization. Journal of Cardiovascular Medicine, 2026, 27, 306-317.	2.3	2
14	Pathway-Guided and Patient-Centred Therapeutic Strategies in Atherosclerotic Cardiovascular Disease. European Journal of Preventive Cardiology, 2026, .	6.1	0
15	Polyvascular Disease by Systematic Vascular Screening and Adverse Outcomes in Patients With Acute Myocardial Infarction. Journal of Cardiovascular Medicine, 2026, 27, 756-763.	2.3	1